

Case report: Adoptive T-cell Tx shows promise in glioblastoma

December 29 2016



(HealthDay)—Treatment with autologous chimeric antigen receptor

(CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13R α 2) is associated with tumor regression in recurrent multifocal glioblastoma, according to a case report published in the Dec. 29 issue of the *New England Journal of Medicine*.

Christine E. Brown, Ph.D., from the City of Hope Beckman Research Institute and Medical Center in Duarte, Calif., and colleagues describe their clinical experience with a patient with recurrent multifocal glioblastoma who received CAR-engineered T cells. Over 220 days, multiple infusions of CAR T cells were administered through two intracranial delivery routes: infusions into the resected tumor cavity followed by infusions into the ventricular system.

The authors did not observe any toxic effects of grade 3 or higher in association with intracranial infusions of IL13R α 2-targeted CAR T cells. Regression of all intracranial and spinal tumors was observed after CAR T-cell treatment, with corresponding increases in cytokine and immune cell levels in the cerebrospinal fluid. This clinical response persisted for 7.5 months after CAR T-cell treatment initiation.

"We report that autologous CAR T [cells](#) targeting IL13R α 2 mediated a transient complete response in a patient with recurrent multifocal glioblastoma, with dramatic improvements in quality of life, including the discontinuation of systemic glucocorticoids and a return to normal life activities," the authors write.

More information: [Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Case report: Adoptive T-cell Tx shows promise in glioblastoma (2016, December 29)
retrieved 1 May 2024 from

<https://medicalxpress.com/news/2016-12-case-t-cell-tx-glioblastoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.